Case Overview: Lawsuits allege Ozempic and Mounjaro manufacturers failed to warn patients about severe gastrointestinal side effects, including gastroparesis (stomach paralysis)

Consumers Affected: Patients prescribed Ozempic, Wegovy, or Mounjaro for diabetes or weight loss

Court: Federal court proceedings underway

Ozempic and Mounjaro Lawsuits Allege Hidden Gastroparesis Risks

Lawsuits against diabetes and weight loss drug manufacturers Novo Nordisk and Eli Lilly allege the companies failed to adequately warn patients about severe gastrointestinal side effects, including gastroparesis—a condition known as stomach paralysis. The litigation targets popular medications Ozempic, Wegovy, and Mounjaro, which have gained widespread use for both diabetes management and weight loss.

According to legal information tracking the litigation, the first lawsuit was filed in August 2023 following a CNN investigative report that highlighted multiple patients suffering from stomach paralysis after using these medications.

Lawsuit Claims Manufacturers Knew of Stomach Paralysis Risk

The lawsuits allege that Novo Nordisk and Eli Lilly knew or should have known about the potential for their GLP-1 receptor agonist drugs to cause gastroparesis and other serious gastrointestinal complications. According to the complaints, the manufacturers failed to provide adequate warnings to both patients and healthcare providers about these risks.

Gastroparesis is a condition where the stomach cannot empty properly, leading to delayed gastric emptying. The lawsuits claim this side effect can cause severe symptoms including persistent nausea, vomiting, abdominal pain, and difficulty eating normal amounts of food. In some cases, patients allegedly require feeding tubes or other medical interventions.

The litigation also alleges that patients experienced other serious gastrointestinal issues beyond gastroparesis, including gastroenteritis and gallbladder disease.

Popular Weight Loss Drugs Under Legal Scrutiny

The lawsuits target several high-profile medications that have become increasingly popular for weight loss:

• Ozempic (semaglutide) — Originally approved for Type 2 diabetes, widely used off-label for weight loss
• Wegovy (semaglutide) — FDA-approved specifically for chronic weight management
• Mounjaro (tirzepatide) — Approved for Type 2 diabetes, also used for weight management

These medications work by slowing gastric emptying and reducing appetite, mechanisms that the lawsuits allege can lead to the severe gastrointestinal complications patients experienced.

CNN Investigation Highlighted Patient Experiences

The legal action follows a July 2023 CNN investigation that brought national attention to patients experiencing stomach paralysis after using Ozempic and Wegovy. The report documented cases of patients who developed gastroparesis symptoms and allegedly found evidence that manufacturers were aware of the potential risks.

According to the lawsuits, this investigative reporting helped reveal a pattern of severe gastrointestinal side effects that patients and their doctors were not adequately warned about when the medications were prescribed.

Failure to Warn Claims Target Inadequate Labeling

The central legal theory in these cases involves failure to warn—the allegation that pharmaceutical companies have a duty to inform patients and healthcare providers about known risks associated with their products. The lawsuits claim that while some gastrointestinal side effects were mentioned in drug labeling, the warnings did not adequately convey the severity or frequency of gastroparesis and related complications.

Plaintiffs argue that had they been properly informed about the risk of stomach paralysis and other severe gastrointestinal issues, they would not have chosen to use these medications or would have been monitored more closely for symptoms.

Related Cases

The Ozempic and Mounjaro litigation represents part of a broader trend of pharmaceutical lawsuits involving popular medications and undisclosed risks.

Lawsuit: Various plaintiffs v. Novo Nordisk and Eli Lilly

Case Number: Multiple federal cases pending

Court: Federal court proceedings

Plaintiffs' Attorney(s): Various firms representing affected patients

Have you or someone you know used Ozempic, Wegovy, or Mounjaro and experienced severe gastrointestinal issues? Share your thoughts in the comments below.

This article is for informational purposes only. Consult your doctor before making any changes to your medication.